Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL

VJHemOnc Podcast

The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients.

While both CAR-T cells and bispecific antibodies have their benefits, there are several factors to consider when evaluating their curative potential in R/R DLBCL. In this podcast, you will hear from Manali Kamdar, MD, University of Colorado, Aurora, CO, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, who share some insights into the value of CAR-T cells and bispecifics in R/R DLBCL, the benefits and drawbacks of these agents, and further comment on their efficacy and curative potential.